{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-010604","form_type":"8-K","ticker":null,"cik":"0001792581","company_name":"Kiromic Biopharma, Inc.","filed_at":"2023-05-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.620333+00:00","generated_at":"2026-06-14T11:51:31.010136+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Kiromic BioPharma issues $2M 25% senior secured convertible note due May 2024","bullets":["Principal $2M, interest 25% p.a. (27% on default), matures May 24, 2024.","Convertible into common stock at $6.50/share, subject to 9.99% beneficial ownership limit and Nasdaq share cap.","Note secured by fixtures, equipment, and intellectual property; senior to equity but may be subordinated to future debt.","Issued to an accredited investor under Section 4(a)(2) exemption; proceeds not specified."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-010604","json":"https://secwatch.observer/filing/0001558370-23-010604.json","markdown":"https://secwatch.observer/filing/0001558370-23-010604.md","text":"https://secwatch.observer/filing/0001558370-23-010604.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1792581/000155837023010604/0001558370-23-010604-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1792581/000155837023010604/krbp-20230524x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T11:51:31.010136+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b872076b1d0c6ab8b8a992661286d8458aa7b2c3","claim":"Kiromic Biopharma, Inc. incurred convertible notes of $2,000,000 with an accredited investor at 25% per annum maturing May 24, 2024.","evidence_excerpt":"On May 24, 2023, Kiromic BioPharma, Inc. (the “Company”) issued a 25% Senior Secured Convertible Promissory Note (the “Note”) to an accredited investor. The Note has a principal amount of $2,000,000, bears interest at a rate of 25% per annum (the “Stated Rate”) and matures on May 24, 2024 (the “Maturity Date”)","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1792581/000155837023010604/0001558370-23-010604-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$2,000,000"},{"label":"Counterparty","value":"an accredited investor"},{"label":"Rate","value":"25% per annum"},{"label":"Maturity","value":"May 24, 2024"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"c6659378d8b20721ef9e36c5b4257340baa5e83b","claim":"Kiromic Biopharma, Inc. entered into 25% Senior Secured Convertible Promissory Note valued at $2,000,000 (effective 2023-05-24).","evidence_excerpt":"On May 24, 2023, Kiromic BioPharma, Inc. (the “Company”) issued a 25% Senior Secured Convertible Promissory Note (the “Note”) to an accredited investor. The Note has a principal amount of $2,000,000, bears interest at a rate of 25% per annum (the “Stated Rate”) and matures on May 24, 2024","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1792581/000155837023010604/0001558370-23-010604-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"notes offering"},{"label":"Value","value":"$2,000,000"},{"label":"Effective","value":"2023-05-24"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}